Focused ultrasound could be a game-changer for urological conditions.

The technology has a significant track record in the treatment of prostate cancer, with more than 40,000 patients treated worldwide and 15 years of follow-up study data. To date, Europe and some regions of Asia have approved the use of focused ultrasound to treat prostate cancer and kidney cancer. In the U.S., two systems have been approved by the Food and Drug Administration (FDA) to treat abnormal prostate tissue, (including prostate cancer and benign prostate hypertrophy (BPH). Additional methods to treat the prostate, including MR-guidance and a trans-urethral approach, are being researched worldwide.

There is also clinical and pre-clinical research happening around the globe to assess the potential of the technology to treat kidney and bladder cancer, acute tubular necrosis, acute kidney injury, kidney stones and ureterocele.

Learn more about focused ultrasound for:

ClinicalStage 35Benign Prostatic Hyperplasia (BPH)DC key
ClinicalStage 35Kidney Cancer
ClinicalStage 35Kidney Stones
ClinicalStage 35Prostate Cancer
EarlyStages 35Acute Kidney Injury
EarlyStages 35Acute Tubular Necrosis
EarlyStages 35Bladder Cancer
EarlyStages 35Ureterocele

In this section

Treatment Sites

Clinical Trials